Comparative analysis of LVAD patients in regard of ischaemic or idiopathic cardiomyopathy: A propensity-score analysis of EUROMACS data

Abstract

Background:

Despite recent advances in management of patients with advanced heart failure, mortality remains high. Aim of this study was to compare impact of different aetiology of ischaemic and idiopathic cardiomyopathy on early outcomes and long-term survival of patients after left ventricular assist device implantation.

Methods:

European Registry for Patients with Mechanical Circulatory Support (EUROMACS) gathers clinical data and follow-up parameters of LVAD recipients. Patients enrolled in the EUROMACS registry with primary diagnosis of either ischaemic (n = 1190) or idiopathic (n = 812) cardiomyopathy were included. Primary Endpoints were early mortality as well as long-term survival. Secondary endpoint were major postoperative adverse events, such as need for rethoracotomy. Additionally, a propensity-score matching analysis was performed for patients with ischaemic (n = 509) and idiopathic (n = 509) cardiomyopathy.

Results:

In terms of basic demographics and baseline parameters the two groups significantly differed as expected before propensity-score matching due to different aetiology of cardiomyopathy. Seven-day (52 (4.4%) versus 18 (2.2%); p = 0.009), 30-day (153 (12.9%) versus 73 (9.0%); p = 0.008) and in-hospital mortality (253 (19.7%) versus 123 (15.1%); p = 0.009) were significantly lower in the idiopathic cardiomyopathy group compared to the ischaemic cardiomyopathy group, whereas after propensity-score matching 30-day (p = 0.169) was comparable and in-hospital mortality (p = 0.051) was almost significant. Kaplan-Meier survival analysis revealed no significant difference in regard of long-term survival after propensity-score matching (Breslow-test p = 0.161 and LogRank-test p = 0.113).

Conclusion:

Though patients with ischaemic and idiopathic cardiomyopathy suffer from different cardiomyopathy aetiologies, 30-day-mortality and long-term survival of both groups were similar leading to the conclusion that covariates predominately influence mortality and survival of ischaemic and idiopathic cardiomyopathies.

Keywords

LVAD EUROMACS outcome survival cardiomyopathy

Get full access to this article

View all access options for this article.

References

Hazebroek

Dennert

Heymans

. Idiopathic dilated cardiomyopathy: possible triggers and treatment strategies. Neth Heart J 2012; 20(7–8): 332–335.

Doesch

Papavassiliu

. Diagnosis and management of ischemic cardiomyopathy: role of cardiovascular magnetic resonance imaging. World J Cardiol 2014; 6(11): 1166–1174.

Tsiouris

Borgi

Karam

, et al. Ischemic versus nonischemic dilated cardiomyopathy: the implications of heart failure etiology on left ventricular assist device outcomes. ASAIO J 2013; 59(2): 130–135.

Fennira

Zairi

Jnifene

, et al. Differences between idiopathic and ischemic dilated cardiomyopathy. Tunis Med 2016; 94(8-9): 535–540.

Sisakian

. Cardiomyopathies: evolution of pathogenesis concepts and potential for new therapies. World J Cardiol 2014; 6(6): 478–494.

Castelli

Fornaro

Ciaccheri

, et al. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management. Circ Heart Fail 2013; 6(5): 913–921.

Zuk

Gahl

Susac

, et al. Mid-term mechanical circulatory support: comparison of single-centre data with the EUROMACS registry. Eur J Cardiothorac Surg 2017; 51(1): 127–134.

Antonides

CFJ

Schoenrath

de By

TMMH

, et al. Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study. ESC Heart Fail 2020; 7(3): 1085–1094.

de By

TMMH

Schweiger

Waheed

, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): first EUROMACS Paediatric (Paedi-EUROMACS) report. Eur J Cardiothorac Surg 2018; 54(5): 800–808.

10.

de By

TMMH

Mohacsi

Gahl

, et al. The European Registry for patients with mechanical circulatory support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report. Eur J Cardiothorac Surg 2018; 53(2): 309–316.

11.

de By

Mohacsi

Gummert

, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): first annual report. Eur J Cardiothorac Surg 2015; 47(5): 770–776.

12.

Akin

Soliman

de By

TMMH

, et al. Causes and predictors of early mortality in patients treated with left ventricular assist device implantation in the European Registry of Mechanical Circulatory Support (EUROMACS). Intensive Care Med 2020; 46(7): 1349–1360.

13.

Reineke

Mohacsi

. New role of ventricular assist devices as bridge to transplantation: European perspective. Curr Opin Organ Transplant 2017; 22(3): 225–230.

14.

Djordjevic

Merkle

Eghbalzadeh

, et al. The outcome of patients with peripartum cardiomyopathy and consecutive implantation of a left ventricular assist device. J Card Surg 2021; 36: 2651–2657.

15.

Kirklin

Naftel

Stevenson

, et al. INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant 2008; 27(10): 1065–1072.

16.

Magnussen

Bernhardt

Ojeda

, et al. Gender differences and outcomes in left ventricular assist device support: the European Registry for Patients with Mechanical Circulatory Support. J Heart Lung Transplant 2018; 37(1): 61–70.

17.

Hulman

Ondrusek

de By

TMMH

, et al. Single centre 12 year experience with durable mechanical circulatory support: comparison with the EUROMACS registry. Bratisl Lek Listy 2021; 122(6): 371–378.

18.

Kammoun

Bennour

Laroussi

, et al. Risk stratification for sudden cardiac death in patients with heart failure: emerging role of imaging parameters. Herz 2021; 46: 550–557.

19.

Broch

Murbræch

Andreassen

, et al. Contemporary outcome in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2015; 116(6): 952–959.

20.

Merlo

Cannatà

Pio Loco

, et al. Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 2020; 22(7): 1111–1121.

21.

Lourenco

Saraiva

Martins

, et al. Ischemic versus non-ischemic cardiomyopathy—are there differences in prognosis? Experience of an advanced heart failure center. Rev Port Cardiol 2011; 30(2): 181–197.

22.

Tompkins

Rieger

Florea

, et al. Comparison of mesenchymal stem cell efficacy in ischemic versus nonischemic dilated cardiomyopathy. J Am Heart Assoc 2018; 7(14): e008460.

23.

Shore

Grau-Sepulveda

Bhatt

, et al. Characteristics, treatments, and outcomes of hospitalized heart failure patients stratified by etiologies of cardiomyopathy. JACC Heart Fail 2015; 3(11): 906–916.

24.

Felker

Shaw

O’Connor

. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002; 39(2): 210–218.

25.

Deng

Brisse

Erren

, et al. Ischemic versus idiopathic cardiomyopathy: differing neurohumoral profiles despite comparable peak oxygen uptake. Int J Cardiol 1997; 61(3): 261–268.

26.

Potapov

Nersesian

Lewin

, et al. Propensity score-based analysis of long-term follow-up in patients supported with durable centrifugal left ventricular assist devices: the EUROMACS analysis. Eur J Cardiothorac Surg 2021; 60(3): 579–587.

27.

Veen

Mokhles

Soliman

, et al. Clinical impact and ‘natural’ course of uncorrected tricuspid regurgitation after implantation of a left ventricular assist device: an analysis of the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). Eur J Cardiothorac Surg 2021; 59(1): 207–216.

28.

Sert

Karahan

Aygun

, et al. Prediction of right ventricular failure after continuous flow left ventricular assist device implantation. J Card Surg 2020; 35(11): 2965–2973.

29.

Løgstrup

Nemec

Schoenrath

, et al. Heart failure etiology and risk of right heart failure in adult left ventricular assist device support: the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). Scand Cardiovasc J 2020; 54(5): 306–314.

30.

Rivas-Lasarte

Kumar

Derbala

, et al. Prediction of right heart failure after left ventricular assist implantation: external validation of the EUROMACS right-sided heart failure risk score. Eur Heart J Acute Cardiovasc Care 2021; 10(7): 723–732.

31.

Shah

Murray

Schultz

, et al. External assessment of the EUROMACS right-sided heart failure risk score. Sci Rep 2021; 11(1): 16064.

32.

Divoky

Maran

Ramu

. Gender differences in ischemic cardiomyopathy. Curr Atheroscler Rep 2018; 20(10): 50.

33.

Löchel

Maukel

Weidner

, et al. Gender differences in psychosocial and clinical characteristics in the European Registry for Patients with Mechanical Circulatory Support. Heart Lung 2021; 50(6): 845–852.